| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/03/2022 | 114.48% | Jefferies | → $8 | Initiates Coverage On | → Buy |
ImmunityBio Questions & Answers
The latest price target for ImmunityBio (NASDAQ: IBRX) was reported by Jefferies on August 3, 2022. The analyst firm set a price target for $8.00 expecting IBRX to rise to within 12 months (a possible 114.48% upside). 1 analyst firms have reported ratings in the last year.
The latest analyst rating for ImmunityBio (NASDAQ: IBRX) was provided by Jefferies, and ImmunityBio initiated their buy rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ImmunityBio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ImmunityBio was filed on August 3, 2022 so you should expect the next rating to be made available sometime around August 3, 2023.
While ratings are subjective and will change, the latest ImmunityBio (IBRX) rating was a initiated with a price target of $0.00 to $8.00. The current price ImmunityBio (IBRX) is trading at is $3.73, which is within the analyst's predicted range.